Clinical Trials Logo

Clinical Trial Summary

To compare the initial versus delayed verteporfin photodynamic therapy (PDT) in combination with conbercept in patients with symptomatic polypoidal choroidal vasculopathy (PCV).


Clinical Trial Description

Polypoidal choroidal vasculopathy (PCV) is characterized by polypoidal choroidal vascular dilatation with or without abnormally branching vascular networks(BVN) on indocyanine green angiography (ICGA). It has been considered to be a subtype of wet age-related macular degeneration(wAMD). PCV is more prevalent in Asian patients than in white patients; nearly half of Chinese patients who was diagnosed with wAMD actually was PCV.

However, recently, the first choice treatment for wAMD has shifted to anti-vascular endothelial growth factor (VEGF) drugs, such as bevacizumab(Avastin,Genentech Inc), ranibizumab (Lucentis, Genentech Inc)and aflibercept (Eylea, Regeneron,Berlin,Germany) from PDT, and the vision improving effect has been confirmed regardless of race or disease subtype. Therefore, eyes with PCV can be treated initially with anti-VEGF drugs, however, they are limited in their ability to resolve polypoidal lesions, for which PDT works effectively.

Combination therapy of PDT and anti-VEGF drugs provides the complementary effects of both treatments, but it remains unknown whether PDT should have been administered at the beginning of treatment or during follow-up of anti-VEGF therapy. The purpose of this study was to compare the 12-months treatment results of initial and delayed PDT combined with conbercept (Lumitin, Chengdu Kang Hong Biotech Co., Ltd., Sichuan, China) for PCV. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02821520
Study type Interventional
Source The Eye Hospital of Wenzhou Medical University
Contact
Status Completed
Phase Phase 4
Start date January 2017
Completion date June 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01469156 - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Recruiting NCT02597855 - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography N/A
Completed NCT02495181 - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Phase 4
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01248117 - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Phase 1/Phase 2
Recruiting NCT04707027 - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept N/A
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Phase 4
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT00383812 - Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy N/A
Completed NCT00837330 - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT05229237 - Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
Not yet recruiting NCT04380974 - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT02815176 - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers N/A
Active, not recruiting NCT00344617 - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Phase 3
Recruiting NCT03929731 - Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
Completed NCT01023295 - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) Phase 2